Amir Hefni seen as the answer for Resolution

Privately-held Resolution Therapeutics, a UK biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, has named Amir Hefni (pictured) as chief executive.

Dr Hefni brings almost 20 years’ experience in drug discovery and development leadership in the biotechnology and pharmaceutical industry and joins Resolution from Swiss pharma giant Novartis (NOVN: VX), where he was the head of cell and gene therapy.

"His wonderful style and experience with both cell therapies and liver disease provide a unique perspective"Prior to that, he served as a global asset head in oncology at mid-size French drugmaker Ipsen (Euronext: IPN), where he was instrumental in launching products in multiple indications, driving significant global brand growth, and developing a rich life cycle management program. Previously, Dr Hefni held various commercials roles with Bristol-Myers Squibb (NYSE: BMY) including executive director, US oncology thoracic lead.